Monitoring health and disease status using clonotype profiles

Patent metadata

Field	Value
Publication number	US-10760133-B2
Application number	US-201715827759-A
Country	US
Kind code	B2
Filing date	Nov 30, 2017
Priority date	Nov 7, 2008
Publication date	Sep 1, 2020
Grant date	Sep 1, 2020

Abstract

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using DNA sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions. Identified biomarkers can be used to determine and/or monitor the disease state for a subject with an associated lymphoid disorder or autoimmune disease or other condition. In particular, the invention provides a sensitive method for monitoring lymphoid neoplasms that undergo clonal evolutions without the need to development alternative assays for the evolved or mutated clones serving as patient-specific biomarkers.

First claim

The invention claimed is:

1. A method for detection of a disease in a patient comprising:
amplifying rearranged T cell receptor (TCR) complementarity determining region 3 (CDR3)-encoding region nucleic acid molecules present in a sample from the patient utilizing a plurality of V-segment oligonucleotide primers and a plurality of J-segment oligonucleotide primers to produce a multiplicity of amplified rearranged TCR CDR3-encoding region DNA molecules;
sequencing the multiplicity of amplified rearranged TCR CDR3-encoding region DNA molecules by high-throughput sequencing (HTS) to produce a TCR clonotype profile comprising at least 10,000 TCR clonotype sequences of 20 to 400 nucleotides in length;
comparing the TCR clonotype profile obtained from the patient with a TCR clonotype profile comprising clonotype sequences of 20 to 400 nucleotides in length obtained from a population of subjects that are not affected by the disease, wherein the TCR clonotype profile obtained from the population of subjects that are not affected by the disease comprises one or more TCRs specific for one or more antigens associated with the disease; and
determining a level of the one or more TCRs specific for the one or more antigens associated with the disease in the TCR clonotype profile obtained from the patient,
wherein the level of the one or more TCRs specific for the one or more antigens associated with the disease in the TCR clonotype profile obtained from the patient indicates the detection of the disease in the patient.

2. The method of claim 1 , wherein the one or more TCRs specific for the one or more antigens associated with the disease comprised in the TCR clonotype profile obtained from the patient have at least 90% sequence identity to the TCRs specific for one or more antigens associated with the disease in the TCR clonotype profile obtained from the population of subjects.

3. The method of claim 1 , wherein the sample from the patient comprises peripheral blood or is derived from peripheral blood.

4. The method of claim 1 , wherein the disease is a cancer, an autoimmune disease, or an infectious disease.

5. A method for detection of a disease in a patient comprising:
amplifying rearranged T cell receptor (TCR) complementarity determining region 3 (CDR3)-encoding region nucleic acid molecules present in a sample from a patient suffering from the disease utilizing a plurality of V-segment oligonucleotide primers and a plurality of J-segment oligonucleotide primers to produce a multiplicity of amplified rearranged TCR CDR3-encoding region DNA molecules;
sequencing the multiplicity of amplified rearranged TCR CDR3-encoding region DNA molecules by high-throughput sequencing (HTS) to produce a TCR clonotype profile comprising at least 10,000 TCR clonotype sequences of 20 to 400 nucleotides in length;
comparing the TCR clonotype profile obtained from the patient with a TCR clonotype profile comprising clonotype sequences of 20 to 400 nucleotides in length obtained from a population of subjects, wherein the TCR clonotype profile obtained from the population of subjects comprises one or more TCRs that correlate with the disease; and
determining a level of the one or more TCRs that correlate with the disease in the TCR clonotype profile obtained from the patient,
wherein the level of the one or more TCRs that correlate with the disease in the TCR clonotype profile obtained from the patient indicates detection of the disease in the patient.

6. The method of claim 5 , wherein the one or more TCRs that correlate with the disease comprised in the TCR clonotype profile obtained from the patient suffering from the disease have at least 90% sequence identity to the TCRs that correlate with the disease in the TCR clonotype profile obtained from the population of subjects.

7. The method of claim 5 , wherein the sample from the patient comprises peripheral blood or is derived from peripheral blood.

8. The method of claim 5 , wherein the disease is a cancer, an autoimmune disease, or an infectious disease.

Assignees

• Adaptive Biotechnologies Corp

Inventors

• Faham Malek
• Willis Thomas

Classifications

• C12Q1/6876

  Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title

• C12N15/11 Primary

  DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity} · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title